Healio Minute

In this edition, Achalasia is associated with higher esophageal cancer risk; FDA rejects bulevirtide for hepatitis D and liver disease; real-world data on colonoscopy prep and more.

Read the full coverage here:

Achalasia associated with five-fold higher risk for esophageal cancer

FDA rejects Gilead's bulevirtide for hepatitis D, compensated liver disease

Polyethylene glycol, ascorbic acid cleanse highly effective for colonoscopy prep

Distal cap-assisted endoscopic mucosal resection safe, effective for fibrotic polyps

FDA backs EndoStim's neurostimulation implant for GERD control

References:

Arieira C, et al. Abstract S589: One-Liter Polyethylene Glycol + Ascorbic Acid Bowel Preparation Delivers High Levels of Adequate and High-Quality Bowel Cleansing for Colonoscopy. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).

Douglas SR, et al. Abstract S130: Distal Cap-Assisted Endoscopic Mucosal Resection Is a Safe and Effective Technique for Resection of Non-Lifting or Adherent Colorectal Polyps: An International, Multicenter, Retrospective Study. Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).

Low EE, et al. Abstract S388: Risk of esophageal cancer in achalasia: A matched cohort study utilizing the veterans affairs achalasia cohort (VA-AC). Presented at: ACG Annual Scientific Meeting; Oct. 21-26, 2022; Charlotte, N.C. (hybrid meeting).

Press Release

Press Release

In this edition, we bring you news and Healio-exclusive interviews from the American Neurological Association Annual Meeting.

Read the full coverage here:

Optimism in older adults improves functional recovery after stroke

Neurologic, neurocognitive symptoms of COVID-19 persist for 1 year after diagnosis

VIDEO: Functional movement disorders diagnosed on presence of positive criteria

Pain, sleep, mood disorders most common comorbidities in patients with narcolepsy

VIDEO: Gene therapy potential treatment target for Duchenne muscular dystrophy

References:

Chamberlain J, et al. Neurogenetics and gene therapy. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.

Huff HV, et al. The neurologic and neurocognitive sequelae following COVID-19 in Lima, Peru: Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.

Lipford MC, et al. Demographic characteristics and comorbidities of patients with narcolepsy: A propensity-score matched cohort study: Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.

Reich SG, et al. Updates on functional neurological disorders. Presented at: American Neurological Association annual meeting; Oct. 23-25, 2022; Chicago.

Sloane KL, et al. Always look on the bright side: Associations of optimism with functional outcomes after stroke. Presented at: American Neurological Association annual meeting; Oct. 23-25; Chicago.

In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson's treatment and more.

Read the full coverage here:

Evaluate headache characteristics to classify as migraine

FDA grants breakthrough device designation for brain implant technology

New genetic engineering company aims to develop neuroactive compounds from plants, fungi

Angiotensin receptor blocker therapy associated with decreased incidence of epilepsy

Theranica announces positive results from clinical trial for migraine treatment device

References:

Diamond M. Migraine, chronic migraine and medication overuse headache: Where are we today? Presented at: PAINWeek; Sept. 6-9, 2022; Las Vegas

Doege C, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.3413.

Press Release.

Press Release

Press Release

In this edition, AGA speaks out on controversial NordICC data; first US patient enrolled in phase 3 trial of obefazimod; 'unprecedented' shift in hepatitis A outbreaks and more.

Read the full coverage here:

AGA speaks out on controversial NordICC data citing modest colonoscopy benefit for CRC

First US patient enrolled in Abivax's phase 3 trial of obefazimod for ulcerative colitis

Shift in hepatitis A outbreaks 'unprecedented' in HAV vaccine era, CDC reports

AGA releases first guideline ranking most effective anti-obesity medications

Inflammatory bowel disease may be causal risk for psoriasis, psoriatic arthritis

References:

Bretthauer M, et al. NEJM. 2022;doi:10.1056/NEJMoa2208375.

Foster MA, et al. MMWR Morb Mortal Wkly Rep. 2022;doi:10.15585/mmwr.mm7139a1.

Freuer D, et al. JAMA Dermatol. 2022;doi:10.1001/jamadermatol.2022.3682.

Grunvuld E, et al. Gastroenterology. 2022; doi: 10.1053/j.gastro.2022.08.045.

Press release

In this edition, COVID-19 patients at risk for post-infection complications; VR for patients with back pain; FDA requests further analysis of Supernus Parkinson's treatment and more.

Read the full coverage here:

COVID-19 patients at risk for neurological complications 1 year post-infection

Patients with back pain benefited from at-home VR program

FDA requests further analysis of Supernus Parkinson's treatment

Erenumab not effective at reducing pain in trigeminal neuralgia

Multiple factors indicate need for additional care after concussion

References:

Andersen ASS, et al. Lancet Neurol. 2022;doi:10.1016/S1474-4422(22)00294-0.

Hou BQ, et al. Clin J Sport Med. 2022;doi:10.1097/JSM.0000000000001057.

Maddox T, et al. At-home virtual reality program for chronic low back pain: Durability of a randomized, placebo-controlled trial to 18-months post-treatment. Presented at: PAINWeek; Las Vegas; Sept. 6-9, 2022.

Press Release

Xu E, et al. Nat Med. 2022;doi:10.1038/s41591-022-02001-z.

In this edition, preventive therapies should be offered for migraines; targeting neuropathic symptoms for poststroke pain; PDE5 inhibitors not associated with lower AD, dementia risk and more.

Read the full coverage here:

Range of preventive therapies should be offered for migraines

Poststroke pain may be controlled by targeting neuropathic symptoms

Treatment with PDE5 inhibitors not associated with reduced risk for AD, dementia

NFL, NFLPA finalize review of updated concussion protocol in wake of Tagovailoa injury

Blunt cerebrovascular injury increases risk for ischemic stroke, requires rapid response

References:

Bottros M. Poststroke pain: What it is, what causes it and how to treat it. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.

Desai RJ, et al. Brain Commun. 2022;doi:10.1093/braincomms/fcac247.

Diamond M. Diamond Headache Clinic migraine track: Prevention, treatment. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.

Press Release

Stone DK. Head and neck injury: Predictors of ischemic stroke. Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.

In this edition, endoscopic hemostasis system cleared by FDA for nonvariceal upper GI bleeding; Infliximab retreatment results in remission in patients with Crohn's disease; men who have sex with men twice as likely to be diagnosed with IBD and more. Read the full coverage here:

Endoscopic hemostasis system cleared by FDA for nonvariceal upper GI bleeding

Infliximab retreatment results in remission in 35% of patients with Crohn's disease

Men who have sex with men twice as likely to be diagnosed with IBD

Obeticholic acid yields fewer deaths, liver transplants in primary biliary cholangitis

Third COVID vaccine provides 'significant boost' in antibody response in patients with IBD

References:

Alexander JL, et al. Lancet Gastroenterol Hepatol. 2022;doi:10.1016/S2468-1253(22)00274-6.

Boschetti G, et al. Am J Gastroenterol. 2022;doi:10.14309/ajg.0000000000001842.

Mansoor E, et al. Gut. 2022;doi:10.1136/gutjnl-2022-328218.

Murillo Perez CF, et al. Gastroenterology. 2022;doi:10.1053/j.gastro.2022.08.054.

Press Release

In this episode, FDA approves Rolvedon to reduce infection incidence; women want more education on sexual health during treatment; abemaciclib regimen shows further signs of benefit and more.

Read the full coverage here:

FDA approves Rolvedon to reduce infection incidence when taking certain anticancer drugs

Women with breast cancer want more education on sexual health during treatment

Abemaciclib regimen shows further signs of benefit in advanced breast cancer subgroup

Cancer-related fatigue may impact balance after breast cancer treatment

Chronic inflammation linked to cognitive difficulties among older breast cancer survivors

References:

Carroll JE, et al. J Clin Oncol. 2022;doi:10.1200/JCO.22.00406.

Goetz MP, et al. Abstract LBA15. Presented at: European Society for Medical Oncology Congress. Sept. 9-13, 2022; Paris.

Huynh V, et al. Ann Surg Oncol. 2022;doi:10.1245/s10434-022-12126-7.

Press Release

Wechsler S, et al. Rehab Oncol. 2022;doi:10.1097/01.REO.0000000000000308.

In this edition, lecanemab study shows reduction in clinical decline for early AD; multimorbidity associated with increased risk for dementia, Crenezumab not effective in treating Alzheimer's disease and more.

Read the full coverage here:

Phase 3 study of lecanemab shows reduction in clinical decline in patients with early AD

Multimorbidity associated with increased risk for dementia

Crenezumab not effective in treating Alzheimer's disease

FDA approves macrocyclic GBCA for contrast-enhanced MRI

Healthy habits in midlife may help delay onset of cognitive decline

References:

Calvin CM, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.32124.

Ostrowitzki S, et al. JAMA Neurol. 2022;doi:10.1001/jamaneurol.2022.2909.

Press Release

Press Release

Small G. What's preventing us from preventing dementia? Presented at: BRAINWeek; Sept. 28-30, 2022; Las Vegas.

In this edition, splash pads reduce child drowning risk but boost diarrhea outbreaks; FDA approves Konvomep for benign gastric ulcers; Xifaxan generic may be stalled until 2029 and more.

Read the full coverage here:

'The water is recycled': Splash pads reduce child drowning risk, boost diarrhea outbreaks

FDA approves Konvomep for benign gastric ulcers, risk reduction for upper GI bleeding

Xifaxan generic may be stalled until 2029 despite tentative FDA approval

Earlier CRC screening with colonoscopy, FIT cost-effective 'irrespective of BMI'

1-year surveillance endoscopy recommended for patients at high risk for gastric cancer

References:

Aluko SK, et al. MMWR Morb Mortal Wkly Rep. 2022;doi:10.15585/mmwr.mm7131a1

Press Release

Press Release

Yamamoto Y, et al. JAMA Netw Open. 2022;doi:10.1001/jamanetworkopen.2022.27667.

Yeoh A, et al. Clin Gastroenterol Hepatol. 2022;doi:10.1016/j.cgh.2022.07.028.